Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Ann Hematol. 2022 Apr;101(4):929-931. doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24.

Authors

Giovanni Caocci^{1

2}, Olga Mulas^{3

4}, Daniela Mantovani³, Alessandro Costa⁴, Andrea Galizia⁴, Luca Barabino⁴, Marianna Greco³, Roberta Murru³, Giorgio La Nasa^{3

4}

Affiliations

¹ Ematologia E CTMO, Ospedale Businco, ARNAS Brotzu, Cagliari, Italy. [email protected].
² Dipartimento Di Scienze Mediche E Sanità Pubblica, Università Di Cagliari, Via Jenner, sn, 09124, Cagliari, Italy. [email protected].
³ Ematologia E CTMO, Ospedale Businco, ARNAS Brotzu, Cagliari, Italy.
⁴ Dipartimento Di Scienze Mediche E Sanità Pubblica, Università Di Cagliari, Via Jenner, sn, 09124, Cagliari, Italy.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunity, Humoral
Nitriles
Primary Myelofibrosis* / drug therapy
Primary Myelofibrosis* / genetics
Pyrazoles
Pyrimidines
RNA, Messenger / genetics
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
Nitriles
Pyrazoles
Pyrimidines
RNA, Messenger
ruxolitinib
BNT162 Vaccine